X4 Pharmaceuticals wanted to create a 3D medical animation for the launch of their therapeutic XOLREMDITM, indicated for the treatment of WHIM syndrome, a rare immunodeficiency disorder. The main goal was to communicate the complexity of WHIM syndrome and how XOLREMDI cuts through this complexity by targeting the underlying cause of the disease.
We first detail the many manifestations of WHIM syndrome and show how myelokathexis (the failure of neutrophils to leave the bone marrow) is present in nearly 100% of patients. Then we introduce how variants of a protein called CXCR4 lead to retention of leukocytes in the bone marrow and reduction of leukocytes circulating in the blood. By targeting this receptor and blocking its activation, leukocytes could better migrate to the periphery to perform their functions.
As it was important to link the protein level to the cellular result, we chose to render a yellow glowing C-terminal “tail” in the CXCR4 variant (the typical location of differences from wild-type CXCR4) and have corresponding yellow glows within the overmature neutrophil.
Creatively, for the cellular story, we chose to have the camera itself behave like a cell. When we describe migration into the circulation, the camera follows, and when we discuss retention in the bone marrow, the camera gets trapped as well.
Clinical data and patient outcomes were intentionally omitted since animation development was concurrent with the timeline of FDA approval and the indication was finalized toward the end of the project.
See how XVIVO can transform your scientific data into a MOA animation with a consultation today: https://xvivo.com/contact-us/
Related Animations
